drugset / Trial / NCT00687999

NIDDM and IR in Combination Therapy for CHC

NCT00687999

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The influence of insulin sensitivity and glucose tolerance on the effects of antiviral therapy for HCV remains unclear. The aim of the present study was (1) To elucidate the clinical and virological factors associated with sustained viral response in patients with combination therapy with PEG-IFN and ribavirin. (2) To clarify the influence of diabetes mellitus (DM), impaired glucose tolerance test (IGT) and insulin resistance (IR) on the HCV response to combination therapy with PEG-IFN and ribavirin. (3) To test the influence of combination therapy on HOMA IR

Timeline

Start
2005-12
Primary completion
2008-06
Completion
2008-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegylated Interferon-alpha Protein / enzyme biologic Subcutaneous
Subject Ribavirin Small molecule 1000 mg Oral
Subject Ribavirin Small molecule 1200 mg Oral